Which has preferable valuation and earnings, PCVX or BIIB?

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Biogen $9.89B 3.30 $1.29B $5.65 39.08

Is PCVX or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 11.18% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Biogen 8.32% 11.18% 6.88%

Does the media prefer PCVX or BIIB?

In the previous week, Biogen had 15 more articles in the media than Vaxcyte. MarketBeat recorded 29 mentions for Biogen and 14 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.12 beat Biogen's score of 1.05 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 17 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCVX or ALNY?

In the previous week, Vaxcyte and Vaxcyte both had 14 articles in the media. Vaxcyte's average media sentiment score of 1.12 beat Alnylam Pharmaceuticals' score of 0.91 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, INSM or PCVX?

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 45.48 -$1.28B -$4.11 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is INSM or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Vaxcyte's return on equity of -37.56% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Vaxcyte N/A -37.56% -33.62%

Does the media favor INSM or PCVX?

In the previous week, Vaxcyte had 3 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Vaxcyte and 11 mentions for Insmed. Vaxcyte's average media sentiment score of 1.12 beat Insmed's score of 0.98 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Vaxcyte N/A -37.56% -33.62%

Does the media refer more to BNTX or PCVX?

In the previous week, Vaxcyte had 12 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Vaxcyte and 2 mentions for BioNTech. Vaxcyte's average media sentiment score of 1.12 beat BioNTech's score of 0.09 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PCVX or INCY?

Incyte has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Incyte $5.14B 5.00 $1.29B $7.85 16.15

Is PCVX or INCY more profitable?

Incyte has a net margin of 27.71% compared to Vaxcyte's net margin of 0.00%. Incyte's return on equity of 29.93% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Incyte 27.71% 29.93% 22.88%

Does the media prefer PCVX or INCY?

In the previous week, Vaxcyte had 1 more articles in the media than Incyte. MarketBeat recorded 14 mentions for Vaxcyte and 13 mentions for Incyte. Incyte's average media sentiment score of 1.28 beat Vaxcyte's score of 1.12 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vaxcyte (PCVX) Competitors

$61.16 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

PCVX vs. BIIB, ALNY, INSM, BNTX, and INCY

Should you buy Vaxcyte stock or one of its competitors? Vaxcyte's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), BioNTech (BNTX), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vaxcyte compare to Biogen?

Vaxcyte (NASDAQ:PCVX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 11.18% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Biogen	8.32%	11.18%	6.88%

Vaxcyte has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 40.61%. Biogen has a consensus price target of $228.50, suggesting a potential upside of 3.47%. Given Vaxcyte's higher possible upside, equities analysts clearly believe Vaxcyte is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Biogen	$9.89B	3.30	$1.29B	$5.65	39.08

In the previous week, Biogen had 15 more articles in the media than Vaxcyte. MarketBeat recorded 29 mentions for Biogen and 14 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.12 beat Biogen's score of 1.05 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	17 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Alnylam Pharmaceuticals?

Vaxcyte (NASDAQ:PCVX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vaxcyte has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

In the previous week, Vaxcyte and Vaxcyte both had 14 articles in the media. Vaxcyte's average media sentiment score of 1.12 beat Alnylam Pharmaceuticals' score of 0.91 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Alnylam Pharmaceuticals	$3.71B	9.59	$313.75M	$5.38	49.46

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Vaxcyte's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Vaxcyte presently has a consensus price target of $86.00, indicating a potential upside of 40.61%. Alnylam Pharmaceuticals has a consensus price target of $386.14, indicating a potential upside of 45.10%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Alnylam Pharmaceuticals beats Vaxcyte on 11 of the 15 factors compared between the two stocks.

How does Vaxcyte compare to Insmed?

Insmed (NASDAQ:INSM) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Insmed presently has a consensus target price of $205.52, indicating a potential upside of 62.74%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 40.61%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Vaxcyte's return on equity of -37.56% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Vaxcyte	N/A	-37.56%	-33.62%

96.8% of Vaxcyte shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.48	-$1.28B	-$4.11	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

In the previous week, Vaxcyte had 3 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Vaxcyte and 11 mentions for Insmed. Vaxcyte's average media sentiment score of 1.12 beat Insmed's score of 0.98 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Summary

Vaxcyte beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Vaxcyte	N/A	-37.56%	-33.62%

BioNTech currently has a consensus price target of $127.44, indicating a potential upside of 22.82%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 40.61%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Vaxcyte had 12 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Vaxcyte and 2 mentions for BioNTech. Vaxcyte's average media sentiment score of 1.12 beat BioNTech's score of 0.09 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Vaxcyte has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	8.08	-$1.29B	-$7.83	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Summary

BioNTech and Vaxcyte tied by winning 8 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Incyte?

Vaxcyte (NASDAQ:PCVX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Incyte has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Incyte	$5.14B	5.00	$1.29B	$7.85	16.15

Incyte has a net margin of 27.71% compared to Vaxcyte's net margin of 0.00%. Incyte's return on equity of 29.93% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Incyte	27.71%	29.93%	22.88%

Vaxcyte currently has a consensus target price of $86.00, indicating a potential upside of 40.61%. Incyte has a consensus target price of $124.05, indicating a potential downside of 2.13%. Given Vaxcyte's higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Incyte	0 Sell rating(s)	12 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.54

Vaxcyte has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Incyte has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

In the previous week, Vaxcyte had 1 more articles in the media than Incyte. MarketBeat recorded 14 mentions for Vaxcyte and 13 mentions for Incyte. Incyte's average media sentiment score of 1.28 beat Vaxcyte's score of 1.12 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Incyte beats Vaxcyte on 13 of the 16 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCVX vs. The Competition

Export

Metric	Vaxcyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.10B	$4.01B	$7.25B	$12.91B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-8.02	12.65	273.27	25.43
Price / Sales	N/A	1,344.31	624.55	95.06
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	2.98	16.39	11.01	6.39
Net Income	-$766.63M	-$22.85M	$3.49B	$358.69M
7 Day Performance	0.69%	1.43%	1.63%	0.22%
1 Month Performance	5.32%	6.00%	4.42%	-0.10%
1 Year Performance	85.22%	49.38%	24.21%	14.04%

Vaxcyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCVX Vaxcyte	2.3805 of 5 stars	$61.16 flat	$86.00 +40.6%	+85.2%	$9.10B	N/A	N/A	160	Positive News Gap Down
BIIB Biogen	3.5004 of 5 stars	$216.65 -0.8%	$227.79 +5.1%	+57.0%	$32.28B	$10.03B	38.35	7,500	Positive News
ALNY Alnylam Pharmaceuticals	4.6184 of 5 stars	$240.69 +1.5%	$386.14 +60.4%	-41.1%	$31.73B	$4.80B	44.74	2,770	Gap Down
INSM Insmed	3.7287 of 5 stars	$121.82 +2.8%	$205.52 +68.7%	-13.0%	$25.89B	$606.42M	N/A	1,664
BNTX BioNTech	3.0027 of 5 stars	$101.61 -0.5%	$127.44 +25.4%	-7.7%	$25.81B	$3.25B	N/A	7,807

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCVX) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Competitors